Validation of the Role of Levetiracetam for Newly Diagnosed GBM Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02815410|
Recruitment Status : Not yet recruiting
First Posted : June 28, 2016
Last Update Posted : June 28, 2016
Seoul National University Hospital
Information provided by (Responsible Party):
Chae-Yong Kim, Seoul National University Hospital
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Not yet recruiting|
|Estimated Primary Completion Date :||June 2019|
|Estimated Study Completion Date :||June 2022|
Kim YH, Kim T, Joo JD, Han JH, Kim YJ, Kim IA, Yun CH, Kim CY. Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme. Cancer. 2015 Sep 1;121(17):2926-32. doi: 10.1002/cncr.29439. Epub 2015 May 14.
Guthrie GD, Eljamel S. Impact of particular antiepileptic drugs on the survival of patients with glioblastoma multiforme. J Neurosurg. 2013 Apr;118(4):859-65. doi: 10.3171/2012.10.JNS12169. Epub 2012 Nov 23. Review.